IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have been given a consensus rating of “Moderate Buy” by the seventeen analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and fifteen have issued a buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $46.60.

A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. BTIG Research restated a “buy” rating and issued a $62.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday, October 21st. UBS Group initiated coverage on IDEAYA Biosciences in a report on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price objective on the stock. New Street Research set a $30.00 target price on IDEAYA Biosciences in a report on Tuesday, October 21st. Finally, Truist Financial boosted their target price on shares of IDEAYA Biosciences from $59.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th.

IDEAYA Biosciences Price Performance

Shares of IDYA opened at $34.47 on Tuesday. The company’s 50-day moving average is $35.01 and its 200-day moving average is $29.41. The firm has a market capitalization of $3.02 billion, a PE ratio of -18.53 and a beta of 0.05. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, November 4th. The company reported $1.33 EPS for the quarter, topping the consensus estimate of ($0.12) by $1.45. The company had revenue of $207.83 million for the quarter, compared to the consensus estimate of $59.98 million. Analysts predict that IDEAYA Biosciences will post -3.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. State of New Jersey Common Pension Fund D boosted its stake in shares of IDEAYA Biosciences by 11.1% in the second quarter. State of New Jersey Common Pension Fund D now owns 100,827 shares of the company’s stock valued at $2,119,000 after buying an additional 10,047 shares during the period. Oppenheimer Asset Management Inc. increased its stake in IDEAYA Biosciences by 19.3% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 13,787 shares of the company’s stock worth $290,000 after acquiring an additional 2,227 shares during the period. Creative Planning raised its holdings in IDEAYA Biosciences by 99.4% in the 2nd quarter. Creative Planning now owns 121,684 shares of the company’s stock valued at $2,558,000 after acquiring an additional 60,667 shares in the last quarter. Signaturefd LLC lifted its position in shares of IDEAYA Biosciences by 58.1% during the 2nd quarter. Signaturefd LLC now owns 4,549 shares of the company’s stock valued at $96,000 after acquiring an additional 1,672 shares during the period. Finally, Fiera Capital Corp grew its holdings in shares of IDEAYA Biosciences by 26.6% during the 2nd quarter. Fiera Capital Corp now owns 1,532,269 shares of the company’s stock worth $32,208,000 after purchasing an additional 322,404 shares in the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.